Biology Network Modeling: New Targets in Hemophilia Therapy Webinar

New therapeutic agents for haemophilia that are in development or already licensed are expected to provide transformative treatment options that address the limitations of current factor-replacement regimens. Many of these new therapies are not based on simply replacing the missing factor and are administered subcutaneously. These novel therapies should significantly reduce treatment burden and increase the ability to deliver prophylaxis for persons with hemophilia with or without inhibitor.